Volker Teichgräber

4.5k total citations · 1 hit paper
27 papers, 2.8k citations indexed

About

Volker Teichgräber is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Volker Teichgräber has authored 27 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Volker Teichgräber's work include Cancer Immunotherapy and Biomarkers (11 papers), Peptidase Inhibition and Analysis (10 papers) and CAR-T cell therapy research (8 papers). Volker Teichgräber is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Peptidase Inhibition and Analysis (10 papers) and CAR-T cell therapy research (8 papers). Volker Teichgräber collaborates with scholars based in Switzerland, United States and Germany. Volker Teichgräber's co-authors include David Masopust, Rafi Ahmed, E. John Wherry, Susan M. Kaech, Rustom Antia, Ulrich H. von Andrian, Todd C. Becker, Erich Gulbins, Michael Weller and Nicole Endlich and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Nature Immunology.

In The Last Decade

Volker Teichgräber

27 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lineage relationship and protective immunity of memory CD8 T cell subsets

2003 1.5k citations E. John Wherry, Volker Teichgräber et al. Nature Immunology profile →

Peers

Countries citing papers authored by Volker Teichgräber

Since Specialization

Citations

This map shows the geographic impact of Volker Teichgräber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Volker Teichgräber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Volker Teichgräber more than expected).

Fields of papers citing papers by Volker Teichgräber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Volker Teichgräber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Volker Teichgräber. The network helps show where Volker Teichgräber may publish in the future.

Co-authorship network of co-authors of Volker Teichgräber

This figure shows the co-authorship network connecting the top 25 collaborators of Volker Teichgräber. A scholar is included among the top collaborators of Volker Teichgräber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Volker Teichgräber. Volker Teichgräber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors 2024 ·Clinical Cancer Research ·Neeltje Steeghs, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, Morten Mau‐Sørensen, Debbie Robbrecht, Josep Tabernero, (unknown), María E. Rodríguez-Ruiz, (unknown), Daniela Schmid, (unknown), Carl Watson, (unknown), David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero	11
2	Investigating the complex interplay between fibroblast activation protein α-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy 2024 ·Frontiers in Immunology ·Anton Kraxner, (unknown), Wei‐Yi Cheng, Tai-Hsien Ou Yang, (unknown), Marta Cañamero, Emilia Andersson, (unknown), Sebastian Dziadek, Ann-Marie E Bröske, Maurizio Ceppi, Tamara Tanos, Volker Teichgräber, Jehad Charo	8
3	A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials 2023 ·Clinical Cancer Research ·David Dejardin, Anton Kraxner, Annika Blank, Natascha Rieder, Volker Teichgräber, Nicolas Städler, Ulrich Beyer, Bruno Gomès, Jehad Charo	4
4	884TiP A phase Ib/II multicenter, randomized, umbrella study evaluating novel treatment combinations in melanoma (MORPHEUS-MELANOMA) 2022 ·Annals of Oncology ·Georgina V. Long, (unknown), Ahmad A. Tarhini, P.A. Ascierto, (unknown), (unknown), (unknown), Volker Teichgräber, Christian U. Blank	3
5	SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma 2020 ·Annals of Oncology ·Vincent Chung, Angela Alistar, Ben George, (unknown), Hedy L. Kindler, Do‐Youn Oh, Simon Allen, Hila Barak, (unknown), (unknown), (unknown), Colby S. Shemesh, Volker Teichgräber, (unknown), Charles D. Lopez	6
6	Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy 2018 ·Clinical Cancer Research ·Benjamin Ribba, Christophe Boetsch, Tapan K. Nayak, Hans Peter Grimm, Jehad Charo, Stefan Evers, Christian Klein, Jean Tessier, (unknown), Alex Phipps, Pavel Pisa, Volker Teichgräber	56
7	Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v) 2018 ·Annals of Oncology ·Ignacio Melero, (unknown), Morten Mau‐Sørensen, Ulrik Lassen, Martijn P. Lolkema, Debbie Robbrecht, Carlos Gomez‐Roca, Juan Martín-Liberal, Josep Tabernero, Willeke Ros, (unknown), Nicolás Isambert, (unknown), Christophe Boetsch, Jehad Charo, Stefan Evers, Volker Teichgräber, Jan H.M. Schellens	18
8	Abstract 5621: FAP-4-1BBL: A novel versatile tumor-stroma targeted 4-1BB agonist for combination immunotherapy with checkpoint inhibitors, T-cell bispecific antibodies, and ADCC-mediating antibodies 2018 ·Cancer Research ·Johannes Sam, Christina Claus, Claudia Ferrara, Sabine M. Lang, Valeria Nicolini, Sara Colombetti, Volker Teichgräber, Stefan Evers, Marina Bacac, Pablo Umaña, Christian Klein	1
9	Schedule optimization of a novel tumor-targeted IL-2 variant immunocytokine by integration of human in vivo immune cell kinetics and functional imaging 2016 ·Annals of Oncology ·Benjamin Ribba, Christophe Boetsch, Tapan K. Nayak, (unknown), Hans Peter Grimm, (unknown), (unknown), Stefan Evers, Volker Teichgräber	1
10	Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro 2015 ·Advances in Medical Sciences ·Volker Teichgräber, Carmen Monasterio, (unknown), Regina Boger, (unknown), Thomas Dieterle, Dirk Jäger, Stefan Bauer	73
11	Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests 2015 ·BMC Health Services Research ·Mogens Vyberg, Søren Nielsen, Rasmus Røge, (unknown), Jim Ranger‐Moore, Eric Walk, (unknown), Ulrich‐Peter Rohr, Volker Teichgräber	16
12	5-Fluorouracil and Interferon-α Immunochemotherapy Enhances Immunogenicity of Murine Pancreatic Cancer Through Upregulation of NKG2D Ligands and MHC Class I 2012 ·Journal of Immunotherapy ·(unknown), Angela Märten, (unknown), Volker Teichgräber, Markus W. Büchler, Dirk Jäger, Jan Schmidt	42
13	Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis 2008 ·Nature Medicine ·Volker Teichgräber, Martina Ulrich, Nicole Endlich, Joachim Riethmüller, Barbara Wilker, (unknown), Anna M. van Heeckeren, Mark L. Barr, Gabriele von Kürthy, Kurt Werner Schmid, Michael Weller, Burkhard Tümmler, Florian Läng, Heike Grassmé, Gerd Döring, Erich Gulbins	460
14	Strength of Stimulus and Clonal Competition Impact the Rate of Memory CD8 T Cell Differentiation 2007 ·The Journal of Immunology ·Surojit Sarkar, Volker Teichgräber, Vandana Kalia, Antonio Polley, David Masopust, Laurie E. Harrington, Rafi Ahmed, E. John Wherry	104
15	Overexpression of Acid Sphingomyelinase Sensitizes Glioma Cells to Chemotherapy 2007 ·Antioxidants and Redox Signaling ·Georgios Grammatikos, Volker Teichgräber, Alexander Carpinteiro, Tanja Trarbach, Michael Weller, Ulrich R. Hengge, Erich Gulbins	43
16	Percutaneous MR-Guided Radiofrequency Ablation of Recurrent Sacrococcygeal Chordomas 2006 ·American Journal of Roentgenology ·Volker Teichgräber, Christophe Aubé, Diethard Schmidt, E. C. Jehle, C. König, Claus D. Claussen, Philippe L. Pereira	12
17	Ceramide-enriched membrane domains 2005 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·(unknown), Volker Teichgräber, Erich Gulbins	275
18	Lineage relationship and protective immunity of memory CD8 T cell subsets breakdown → 2003 ·Nature Immunology ·E. John Wherry, Volker Teichgräber, Todd C. Becker, David Masopust, Susan M. Kaech, Rustom Antia, Ulrich H. von Andrian, Rafi Ahmed	1486
19	High frequency of human cytomegalovirus (HCMV)-specific CD8 + -T cells detected in a healthy CMV-seropositive donor 2002 ·Cellular and Molecular Life Sciences ·Karl S. Lang, Arnaud Moris, Cécile Gouttefangeas, Steffen Walter, Volker Teichgräber, (unknown), Dorothee Wernet, Klaus Hamprecht, Hans‐Georg Rammensee, Stefan Stevanović	27
20	Cutting Edge: Characterization of Allorestricted and Peptide-Selective Alloreactive T Cells Using HLA-Tetramer Selection 2001 ·The Journal of Immunology ·Arnaud Moris, Volker Teichgräber, Laurent Gauthier, Hans‐Jörg Bühring, Hans‐Georg Rammensee	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact